Nature Medicine, Published online: 06 August 2026; doi:10.1038/s41591-026-04557-6
In this phase 1 dose-escalation trial, intracranial delivery of B7-H3-targeting chimeric antigen receptor T cell therapy in patients with glioblastoma showed no dose-limiting toxicity signals and encouraging signals of clinical benefit.
